NMDS Group logo

NMDS Group

pdf Publications

Documents

default Ex Vivo expanded adaptive NK cells effectively kill primary acute lymphoblastic leukemia cells (31 downloads)
default SF3B1-initiating Mutations in MDS with ring sideroblasts target lymphomyeloid hematopoietic stem cells (28 downloads)
default The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes (30 downloads)
default Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance (38 downloads)
default Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease (39 downloads)
default The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes (60 downloads)
default Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel (115 downloads)
default Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome (36 downloads)
default Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations (42 downloads)
default Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice (56 downloads)
default Evaluating variant calling tools for non-matched next-generation sequencing data (62 downloads)
default Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia (50 downloads)
default Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality (202 downloads)
default GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (248 downloads)
default Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes (29 downloads)
default Mutations in histone modulators are associated with prolonged survival during azacitidine therapy (438 downloads)
default The European Hematology Association Roadmap for European Hematology Research: a consensus document (56 downloads)
default Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts (391 downloads)
default Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome (200 downloads)
default Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry (312 downloads)
default SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts (493 downloads)
default Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells (22 downloads)
default High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia (373 downloads)
default Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes (382 downloads)
default Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes (28 downloads)
default Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studie (294 downloads)
default Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes (21 downloads)
default Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study (373 downloads)
default Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia (29 downloads)
default Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes (30 downloads)
default A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome (467 downloads)
default Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo (26 downloads)
default A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine (408 downloads)
default A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome (28 downloads)
default p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) (22 downloads)
default Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo (467 downloads)
pdf Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial (389 downloads)
default Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation (377 downloads)
default Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients (349 downloads)
default Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model (19 downloads)
default Clinical and biological implications of driver mutations in myelodysplastic syndromes (445 downloads)
default Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet (30 downloads)
default Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes (361 downloads)
default Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis (17 downloads)
default A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial (19 downloads)
default Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions (26 downloads)
default The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts (28 downloads)
default Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis (20 downloads)
default Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 (28 downloads)
default Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group (19 downloads)
default Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes (27 downloads)
default Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q (16 downloads)
pdf Evaluation of Azacitidine in transfusion-dependent, Epo-refractory patients with lower-risk MDS ( pdf, 83 KB ) (501 downloads)
default Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML (25 downloads)
default Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms (27 downloads)
default Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks (30 downloads)
default Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts (23 downloads)
default Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome (27 downloads)
default Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes (17 downloads)
default TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression (24 downloads)
pdf Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities (331 downloads)
default Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes (18 downloads)
pdf Significance of JAK2 and TET2 mutations in myelodysplastic syndromes (411 downloads)
default Persistent malignant stem cells in del(5q) myelodysplasia in remission (29 downloads)
default Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine (17 downloads)
pdf Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy (333 downloads)
default Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C (17 downloads)
default Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia (18 downloads)
default Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression (17 downloads)
pdf Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (321 downloads)
pdf Erythropoietin and G-CSF treatment associated with improved survival in myelodysplastic syndrome (395 downloads)
pdf Supportive care, growth factors, and new therapies in myelodysplastic syndromes (369 downloads)
default Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update (19 downloads)
default The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update (18 downloads)
pdf Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome (249 downloads)
default The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes (18 downloads)
pdf Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes (304 downloads)
default Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations (16 downloads)
default Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes (18 downloads)
pdf Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF (359 downloads)
pdf The WHO classification of MDS does make a difference (349 downloads)
pdf No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease (281 downloads)
pdf A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life (302 downloads)
default Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8 (21 downloads)
default Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level (21 downloads)

Meetings

News

Patient information